NCT07279714CompletedPhase 2
Fisetin in Mild Alzheimer's Disease
Fisetin Intervention Study in Mild Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 20 Aug 2026
Brief summary (registry, in English)
This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- First submitted
- 17 Nov 2025
- Start date
- 27 Jan 2026
- Primary completion date
- 21 Jul 2026
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Diseases
- Alzheimer disease
- NCT number
- NCT07279714
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 5
- From 27 Jan 2026 to the primary completion date, 21 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known hypersensitivity or allergy to fisetin
- Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial
- Unstable medical disorders
- Ongoing treatment for active infection with antibiotics/antifungals
- Ongoing treatment for cancer
- Active alcohol or substance use disorder
- Recent active bleeding
- Patients taking oral anticoagulants, anti-cancer, anti-seizure medications, or other medications that could have a significant interaction with fisetin
- Other neurologic or neurodegenerative conditions impacting cognition
Other
- Use within the last month of other senolytic supplements, antioxidant supplements, natural health products
- Active Major Depressive Episode, active suicidal thoughts or psychosis
- Any thing that would preclude the ability to undergo an MRI scan
Who the study is looking for
- Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia
- Moca score of 11 or higher
- Stable psychotropics and cognitive enhancing medications
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sunnybrook Research Institute Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.